Core Insights - Myriad Genetics, Inc. announced a study showing that the use of an online screening tool and education significantly increased the completion rate of hereditary cancer testing among patients [1][2][3] Study Findings - The study evaluated the impact of MyGeneHistory®, an online patient screening tool, and a virtual education program on hereditary cancer testing completion rates [2][6] - Approximately 30% more patients were identified as meeting the guidelines for hereditary cancer testing (HCT) after implementing the online tool [8] - There was a 50% increase in the number of patients who met the guidelines and were offered HCT [8] - More than twice the number of patients completed HCT following the implementation of the new tools [8] Clinician Feedback - Clinicians reported increased confidence in administering hereditary cancer risk assessments, with 87% stating that the online screening and education tools helped them adhere to recommended standards of care [3] - Over 80% of providers believed the program assisted them in following ACOG guidelines for hereditary cancer risk assessment [3] Program Overview - Myriad's Breast Cancer Risk Assessment Program includes the MyRisk® with RiskScore® Hereditary Cancer Test and the MyGeneHistory online screening tool [5] - The program aims to improve patient access and education regarding genetic testing [4][5] Study Details - The study involved over 10,000 patients across five U.S. community obstetrics/gynecology practices, with an eight-week observation period followed by training on the online tools [6]

SALT LAKE CITY, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced select unaudited preliminary results for the fourth quarter and full year ended December 31, 2024, and provided full year 2025 financial guidance. Select Preliminary Fourth Quarter and Full Year 2024 Financial ResultsThe company expects the following: Fourth quarter of 2024 total revenues to be between $209 million and $211 million, an increase of approxi ...

Myriad Genetics, Inc. (MYGN) recently announced an agreement with Hannah Storm, a nationally renowned sports broadcaster who recently revealed her battle with breast cancer. Under the agreement, Storm will act as an ambassador for the Myriad Genetics Breast Cancer Risk Assessment Program, which features the MyRisk with RiskScore Hereditary Cancer test.The latest collaboration with Storm will bolster the company’s Hereditary Cancer testing business. MYGN Stock’s Likely Trend Following the NewsMyriad Genetic’ ...

Company Announcement - Myriad Genetics announced a partnership with Hannah Storm, a renowned sports broadcaster, to promote the Myriad Genetics Breast Cancer Risk Assessment Program [1] - Hannah Storm will serve as an ambassador for the MyRisk with RiskScore Hereditary Cancer Test, the industry-leading hereditary cancer and polygenic risk prediction test [2] - The partnership aims to raise awareness about the importance of family health history in understanding cancer risks [2] Product Details - MyRisk with RiskScore evaluates 48 genes associated with hereditary cancer risk and provides a five-year and lifetime breast cancer risk assessment [6] - The test identifies genetic changes linked to increased cancer risk for 11 different cancers and combines this with family history and clinical factors like breast density [6] Awareness Campaign - Hannah Storm will share content on her social media platforms about the importance of knowing family health history and having conversations about hereditary cancers [5] - The campaign will encourage women to discuss their family health history with healthcare providers and consider preventive steps [5] Industry Impact - Myriad Genetics is a leader in genetic testing and precision medicine, focusing on advancing health and well-being through genetic insights [7] - The company develops genetic tests that assess disease risk, guide treatment decisions, and improve patient care while lowering healthcare costs [7] Personal Story - Hannah Storm was diagnosed with stage zero Ductal Carcinoma in Situ (DCIS) in January 2024, detected through a routine mammogram and subsequent tests [4] - She emphasizes the importance of genetic testing for early detection and understanding potential hereditary risks for her daughters [3]

News release updated to include the members of the management team speaking at the conference. SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, President and CEO, and Sam Raha, COO, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15, at 3:45pm PT (6:45pm ET). The presentation will be available through a live webcast in the investor rel ...

SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced members of its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15, at 3:45pm PT (6:45pm ET). The presentation will be available through a live webcast in the investor relations section of Myriad’s website at investor.myriad.com. An archived edition of the presentation will be available ...

HOUSTON and SALT LAKE CITY, Jan. 07, 2025 (GLOBE NEWSWIRE) -- The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad’s molecular residual disease (MRD) assay. This strategic alliance brings together the longstanding oncology diagnostic experience of Myriad Genetics and the clinical and translational research expertise of MD Anderson to create a portfolio of studies to evaluate ...

SALT LAKE CITY, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its Quality, Innovation, and Corporate Responsibility Report, highlighting key efforts that reflect its commitment to conduct operations as a responsible corporation in the healthcare industry. “Quality, innovation and corporate responsibility are at the heart of what we do at Myriad Genetics,” said Paul J. Diaz, President and CEO, Myriad Genetics. “In co ...

SALT LAKE CITY, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic testing and precision medicine, announced that a MyRisk® Hereditary Cancer Test with RiskScore® study has been named in the American Journal of Human Genetics as one of its top 10 significant advances in genomic medicine. The study was selected by the Genomic Medicine Working Group at the National Human Genome Research Institute. The study by Mabey et al., “Validation of a clinical breast ...

SALT LAKE CITY, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic and genomic testing and precision medicine, announced that a MyRisk® Hereditary Cancer Test with RiskScore® study has been named in the American Journal of Human Genetics as one of its top 10 significant advances in genomic medicine. The study was selected by the Genomic Medicine Working Group at the National Human Genome Research Institute. The study by Mabey et al., "Validation of a clinical breast c ...